We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.37B
AUM Growth
+$113M
Cap. Flow
+$184M
Cap. Flow %
13.39%
Top 10 Hldgs %
57.14%
Holding
78
New
18
Increased
12
Reduced
20
Closed
17

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$69.7M
2
ABBV icon
AbbVie
ABBV
+$66.1M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$52.5M
4
SYK icon
Stryker
SYK
+$43M
5
REPL icon
Replimune Group
REPL
+$37.7M

Top Sells

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$86.5M
2
ELAN icon
Elanco Animal Health
ELAN
+$51.7M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$19.3M
4
COGT icon
Cogent Biosciences
COGT
+$14.4M
5
INCY icon
Incyte
INCY
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SVRA icon
26
Savara
SVRA
$1.13B
$16.8M 1.22%
5,471,299
-191,251
-3% -$667K
JANX icon
27
Janux Therapeutics
JANX
$935M
$13.6M 0.99%
253,262
+88,492
+54% +$4.68M
BIOA
28
BioAge Labs
BIOA
$968M
$13.3M 0.97%
2,304,901
– –
INZY
29
DELISTED
Inozyme Pharma
INZY
$11.9M 0.86%
4,280,308
– –
LLY icon
30
Eli Lilly
LLY
$1.07T
$11.1M 0.81%
+14,364
New +$11.9M
EWTX icon
31
Edgewise Therapeutics
EWTX
$4.39B
$10.8M 0.78%
402,773
+18,006
+5% +$573K
PHVS icon
32
Pharvaris
PHVS
$2.39B
$10.7M 0.78%
560,723
-39,579
-7% -$815K
JBIO
33
Jade Biosciences
JBIO
$1.22B
$9.96M 0.73%
107,391
– –
NARI
34
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.21M 0.67%
180,456
+90,129
+100% +$4.43M
SNDX icon
35
Syndax Pharmaceuticals
SNDX
$1.84B
$8.71M 0.63%
658,627
-128,372
-16% -$2.2M
AXSM icon
36
CALL
Axsome Therapeutics
AXSM
$12.4B
$8.46M 0.62%
+100,000
New +$9.2M
INBX icon
37
Inhibrx
INBX
$1.2B
$8.12M 0.59%
527,190
-8,878
-2% -$135K
IMNM icon
38
Immunome
IMNM
$2.52B
$7.93M 0.58%
746,824
+70,058
+10% +$847K
COGT icon
39
Cogent Biosciences
COGT
$6.79B
$6.42M 0.47%
823,160
-1,442,070
-64% -$14.4M
ACHV icon
40
Achieve Life Sciences
ACHV
$626M
$4.6M 0.34%
1,306,482
-207,550
-14% -$940K
ERAS icon
41
Erasca
ERAS
$6.63B
$4.51M 0.33%
1,795,880
-46,788
-3% -$128K
ESTA icon
42
Establishment Labs
ESTA
$2.72B
$4.39M 0.32%
95,305
-86,171
-47% -$3.76M
AVTR icon
43
Avantor
AVTR
$7.81B
$4.21M 0.31%
+200,000
New +$4.5M
EW icon
44
Edwards Lifesciences
EW
$47.6B
$2.96M 0.22%
40,000
-162,898
-80% -$11.4M
EXAS
45
DELISTED
Exact Sciences
EXAS
$2.92M 0.21%
52,042
+14,405
+38% +$896K
IMTX icon
46
Immatics
IMTX
$1.24B
$2.44M 0.18%
343,206
-42,894
-11% -$369K
DHR icon
47
Danaher
DHR
$135B
$2.3M 0.17%
+10,000
New +$2.46M
NXTC icon
48
NextCure
NXTC
$17.3M
$2.06M 0.15%
222,655
– –
ANAB icon
49
AnaptysBio
ANAB
$1.6B
$1.76M 0.13%
+132,927
New +$3.22M
KROS icon
50
Keros Therapeutics
KROS
$199M
$1.51M 0.11%
+95,375
New +$4.96M
1
2
3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2024 Portfolio in Review

As of Q4 2024, Sofinnova Investments held 78 positions worth $1.37B, up 9% from $1.26B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Sofinnova Investments deployed $184M of net new capital in Q4 2024, opening 18 new positions and adding to 12 existing holdings. Its largest new stake was Gilead Sciences: 774,227 shares worth $71.5M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was IDEAYA Biosciences, an estimated $19.3M trimmed.

  • Sofinnova Investments's largest Q4 2024 buy was Gilead Sciences: 774,227 shares worth $71.5M.
  • Sofinnova Investments added most to Replimune Group in Q4 2024, an estimated $37.7M increase.
  • Sofinnova Investments's biggest Q4 2024 reduction was IDEAYA Biosciences, cutting an estimated $19.3M.
  • Sofinnova Investments fully exited Novo Nordisk in Q4 2024, selling an estimated $86.5M.
  • Sofinnova Investments's ten largest holdings make up 57% of its $1.37B portfolio in Q4 2024.
  • Sofinnova Investments opened 18 new positions and closed 17 in Q4 2024.
  • Sofinnova Investments's portfolio value rose 9% quarter-over-quarter to $1.37B.

Based on Sofinnova Investments's 13F filing for Q4 2024, filed 14 Feb 2025.